NCT07571616

Brief Summary

This was a single-center, open-label, single-arm, exploratory human study evaluating NatureU Pelvic Health Pumpkin Seed in adult women with urinary frequency and urinary leakage symptoms. Twenty-seven participants were recruited, 19 were screened and enrolled, and 19 completed the study and were included in the effectiveness analysis. Participants took the study product for 7 consecutive days, one tablet after lunch and one tablet after dinner, for a total daily intake of two tablets. Outcomes were assessed before product intake and after 7 days of use. The main outcomes included the Women Toileting Behavior Scale (WTBS) and the Incontinence Quality of Life questionnaire (I-QOL). Patient Global Impression of Improvement (PGI-I), waist circumference, fasting blood glucose, blood pressure, and safety observations were also assessed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 15, 2024

Completed
7 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 22, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 22, 2024

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

April 30, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 6, 2026

Completed
Last Updated

May 6, 2026

Status Verified

April 1, 2026

Enrollment Period

7 days

First QC Date

April 30, 2026

Last Update Submit

April 30, 2026

Conditions

Keywords

NatureU Pelvic Health Pumpkin Seedpumpkin seed extractsoybean extractpelvic healthurinary leakageWomen Toileting Behavior Scale

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline in Women Toileting Behavior Scale Total Score

    The Women Toileting Behavior Scale was used to assess urinary behavior. The primary endpoint was the within-participant change in WTBS total score from Day 0 to Day 8 after 7 days of product intake.

    Baseline and Day 8 after 7 days of product intake

Secondary Outcomes (1)

  • Change From Baseline in Incontinence Quality of Life Total Score

    Baseline and Day 8 after 7 days of product intake

Other Outcomes (2)

  • Patient Global Impression of Improvement

    Day 8 after 7 days of product intake

  • Safety and Tolerability During Product Intake

    Baseline through Day 8

Study Arms (1)

NatureU Pelvic Health Pumpkin Seed

EXPERIMENTAL

Participants received NatureU Pelvic Health Pumpkin Seed, one tablet after lunch and one tablet after dinner each day for 7 consecutive days.

Dietary Supplement: NatureU Pelvic Health Pumpkin Seed

Interventions

NatureU Pelvic Health Pumpkin Seed is an oral functional food product containing pumpkin seed extract, soybean extract, vitamin D3, sorbitol, maltodextrin, microcrystalline cellulose, and magnesium stearate. Participants took one tablet after lunch and one tablet after dinner each day for 7 consecutive days.

NatureU Pelvic Health Pumpkin Seed

Eligibility Criteria

Age35 Years - 55 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsThe study population was limited to adult women because the study evaluated female urinary frequency and urinary leakage symptoms.
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Participants who signed informed consent before the study and understood the study content, procedures, and possible adverse reactions.
  • Adult women aged 35 to 55 years, inclusive, with urinary frequency and urinary leakage symptoms.
  • Body weight at least 50 kg and body mass index between 18.5 and 23.9 kg/m2, inclusive.
  • Participants able to maintain normal healthy routines and abstain from alcohol during the study period.

You may not qualify if:

  • Pregnant or breastfeeding women, or women with recent pregnancy plans.
  • Known allergy or hypersensitivity to product ingredients, including pumpkin or soybean, or a history of multiple food allergies.
  • Diagnosed diabetes or other metabolic disease.
  • Clinically significant abnormalities in blood glucose, blood pressure, physical examination, or vital signs as judged by the investigator.
  • Acute or chronic inflammatory disease, including influenza A, within the previous month.
  • Participation in any other clinical trial within 1 month before first use of the study product.
  • Clinically significant disease within the previous 6 months judged by the investigator to make participation inappropriate.
  • Acute illness or concomitant medication use from screening to first use of the study product.
  • Surgery within the previous 3 months.
  • Blood donation or major blood loss greater than 450 mL within the previous 3 months.
  • Difficulty swallowing or a gastrointestinal disease history affecting product intake.
  • Any disease that increases bleeding risk, such as hemorrhoids, acute gastritis, or gastric or duodenal ulcer.
  • Use of prescription or non-prescription medications affecting nutritional supplements or hormone levels.
  • Substantial weight change within the previous month.
  • Any other factor judged by the investigator to make participation inappropriate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dao County People's Hospital

Yongzhou, Hunan, 425300, China

Location

MeSH Terms

Conditions

Urinary Incontinence

Condition Hierarchy (Ancestors)

Urination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Luke Law, Dr

    OmniSolutions Laboratory Holdings Limited

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
The study was open-label with no masking.
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: Participants received NatureU Pelvic Health Pumpkin Seed for 7 consecutive days in a single-arm self-controlled exploratory design.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 30, 2026

First Posted

May 6, 2026

Study Start

July 15, 2024

Primary Completion

July 22, 2024

Study Completion

July 22, 2024

Last Updated

May 6, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared due to privacy protection and ethical considerations.

Available IPD Datasets

Clinical Study Report Access

Locations